James Carroll
President & Chief Executive Officer RNA NanoBiotics
James Carroll is the President and CEO of RNA NanoBiotics, Inc., a company pioneering targeted RNA nanotechnology for oncology. A seasoned executive and investor, he brings over 25 years of leadership experience across the life sciences sector, including roles as Chief Commercial Officer at Bionostics and senior positions at Waters Corporation and Bio-Rad. James is also the President of the Wharton Alumni Angels, leading a network of over 400 investors. His expertise spans company building, strategic commercialization, and raising capital for early-stage biotech ventures, with a deep focus on novel therapeutic platforms.
Seminars
The RNAi therapeutics landscape is rapidly evolving, with breakthroughs in delivery, efficacy, and commercialization reshaping investor expectations. Key discussion points will include clinical differentiation, market potential, and exit strategies, offering a reality check on valuation drivers and red flags.
- Prioritizing delivery platform versatility as a key value driver, enabling investors to back RNAi companies with broad therapeutic applicability
- Assessing clinical milestones beyond knockdown efficiency, including durability and patient-centric endpoints, to identify therapies with superior commercial potential
- Balancing platform validation with indication selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success
- Developing programmable RNA origami structures that self-assemble into precise nanocarriers enabling tissue-specific delivery with reduced off-target effects
- Incorporating conditional stability triggers that respond to cellular microenvironment cues for controlled payload release at disease sites
- Demonstrating encapsulation efficiency through optimized nanostructure design significantly improving therapeutic payload delivery
